Eris Lifesciences Ltd., a leading Indian branded formulations company, today announced the expansion of its Sterile Injectables footprint through the acquisition of 51% equity stake in Swiss Parenterals Ltd. for a consideration of INR 637.50 crore. This deal also marks the entry of Eris into
The company expects this approval for Meropenem 500mg, Meropenem 1000mg, Meropenem 2000mg, Oxaliplatin 5mg/ml, Paclitaxil 6mg/ml, Cisplatin 1mg/ml, Imipenem/Cilastatin 500mg/500mg of its Carbapenem & Oncology production facilities in Baddi to pave the way for GMP certifications from European Medicines Agency and other Pharmaceutical Inspection
Semaglutide, a GLP-1 receptor analogue (GLP-1 RA), indicated for the management of type 2 diabetes has been developed in an oral formulation for the first time. Oral semaglutide will be a gamechanger for people with type 2 diabetes who prefer oral medications over injections. was
